Spotlight on olanzapine/fluoxetine in acute bipolar depression

CNS Drugs

Volumn 22, Issue 9, 2008, Pages 793-795

  Deeks, Emma D ^a,b   Keating, Gillian M ^a,b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

Adis Spotlights; Antipsychotics, therapeutic use; Bipolar depression, treatment; Olanzapine fluoxetine, adverse reactions; Olanzapine fluoxetine, pharmacodynamics; Olanzapine fluoxetine, therapeutic use; Serotonin reuptake inhibitors, therapeutic use

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; FLUOXETINE PLUS OLANZAPINE; GLUCOSE; LAMOTRIGINE; LIPID; OLANZAPINE; PLACEBO; PROLACTIN; SEROTONIN UPTAKE INHIBITOR;

ASTHENIA; AUTOMUTILATION; BIPOLAR DEPRESSION; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG METABOLISM; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; INCREASED APPETITE; LIPID BLOOD LEVEL; MANIA; MONOTHERAPY; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; QUALITY OF LIFE; SEDATION; SHORT SURVEY; SIDE EFFECT; SOMNOLENCE; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; TREATMENT OUTCOME; TREMOR; UNITED STATES; WEIGHT GAIN; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; DRUG COMBINATIONS; FLUOXETINE; HUMANS;

EID: 49549090647     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200822090-00006     Document Type: Short Survey

References (14)

1. Deeks ED, Keating GM. Olanzapine/fluoxetine: a review of its use in the treatment of acute bipolar depression. Drugs 2008; 68 (8): 1115-37
2. Bhana N, Perry CM. Olanzapine: a review of its use in the treatment of bipolar I disorder. CNS Drugs 2001; 15 (11): 871-904
3. Yatham LN, Goldstein JM, Vieta E, et al. Atypical antipsychotics in bipolar depression: potential mechanisms of action. J Clin Psychiatry 2005; 66 Suppl. 5: 40-8
4. Eli Lilly and Company. Symbyax® (olanzapine and fluoxetine HCL capsules): US prescribing information [online]. Available from URL: http://pi.lilly.com/us/symbyax-pi.pdf [Accessed 2007 Oct 17]
5. Hurst M, Lamb HM. Fluoxetine: a review of its use in anxiety disorders and mixed anxiety and depression. CNS Drugs 2000; 14 (1): 51-80
6. Benfield P, Heel RC, Lewis SP. Fluoxetine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1986; 32: 481-508
7. Koch S, Perry KW, Bymaster FP. Brain region and dose effects of an olanzapine/fluoxetine combination on extracellular monoamine concentrations in the rat. Neuropharmacology 2004 Feb; 46 (2): 232-42
8. Zhang W, Perry KW, Wong DT, et al. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology 2000 Sep; 23 (3): 250-62
9. Maragnoli ME, Fumagalli F, Gennarelli M, et al. Fluoxetine and olanzapine have synergistic effects in the modulation of fibroblast growth factor 2 expression within the rat brain. Biol Psychiatry 2004 Jun 1; 55 (11): 1095-102
10. Gossen D, de Suray J-M, Vandenhende F, et al. Influence of fluoxetine on olanzapine pharmacokinetics. AAPS PharmSci 2002; 4 (2): E11
11. Bergemann N, Frick A, Parzer P, et al. Olanzapine plasma concentration, average daily dose, and interaction with co-medication in schizophrenic patients. Pharmacopsychiatry 2004 Mar; 37 (2): 63-8
12. Brown EB, McElroy SL, Keck Jr PE, et al. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry 2006 Jul; 67 (7): 1025-33
13. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003 Nov; 60 (11): 1079-88
14. Shi L, Namjoshi MA, Swindle R, et al. Effects of olanzapine alone and olanzapine/fluoxetine combination on health-related quality of life in patients with bipolar depression: secondary analyses of a double-blind, placebo-controlled, randomized clinical trial. Clin Ther 2004 Jan; 26 (1): 125-34